AbbVie's beat fueled by demand for Humira, Hep C drugs

(Reuters) - AbbVie Inc reported a better-than-expected quarterly profit on Thursday, driven by higher sales of its rheumatoid arthritis treatment Humira and its Hepatitis C drugs, leading the company to raise its full-year earnings forecast.